NASDAQ:AKER - Akers Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.06 +0.01 (+0.95 %) (As of 03/19/2019 01:34 AM ET)Previous Close$1.0615Today's Range$1.01 - $1.1052-Week Range$0.57 - $7.84Volume374,400 shsAverage Volume429,773 shsMarket Capitalization$13.23 millionP/E RatioN/ADividend YieldN/ABeta-0.94 ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey. Receive AKER News and Ratings via Email Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKER Previous Symbol CUSIPN/A CIK1321834 Webwww.akerslaboratories.com Phone856-848-8698Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.93 million Price / Sales3.37 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.01Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,360,000.00 Net Margins-346.69% Return on Equity-107.79% Return on Assets-85.96%Miscellaneous EmployeesN/A Outstanding Shares12,483,000Market Cap$13.23 million Next Earnings Date4/2/2019 (Estimated) OptionableNot Optionable Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions What is Akers Biosciences' stock symbol? Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER." How were Akers Biosciences' earnings last quarter? Akers Biosciences Inc (NASDAQ:AKER) announced its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) EPS for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter. Akers Biosciences had a negative net margin of 346.69% and a negative return on equity of 107.79%. View Akers Biosciences' Earnings History. When is Akers Biosciences' next earnings date? Akers Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Akers Biosciences. Has Akers Biosciences been receiving favorable news coverage? News coverage about AKER stock has trended somewhat positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akers Biosciences earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are some of Akers Biosciences' key competitors? Some companies that are related to Akers Biosciences include Allergy Therapeutics (AGY), Asterias Biotherapeutics (AST), Noxopharm (NOX), ANCHIANO THERAP/S (ANCN), Yourgene Health (YGEN), Biotron (BIT), BIOLASE (BIOL), Daxor (DXR), PLx Pharma (PLXP), Lipocine (LPCN), Five Star Senior Living (FVE), Entera Bio (ENTX), Protech Home Medical (PHM), Evogene (EVGN) and Immunodiagnostic Systems (IDH). What other stocks do shareholders of Akers Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include Biopharmx (BPMX), Neovasc (NVCN), Anavex Life Sciences (AVXL), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), 22nd Century Group (XXII), New Age Beverages (NBEV), Magnegas Applied Tchnlgy Sltns (MNGA), Pareteum (TEUM) and Aytu Bioscience (AYTU). Who are Akers Biosciences' key executives? Akers Biosciences' management team includes the folowing people: Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial OperationsMs. Pamela E. Hibler, VP of Sales & Distribution Who are Akers Biosciences' major shareholders? Akers Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (2.60%), BlackRock Inc. (1.32%), Geode Capital Management LLC (0.64%), Geode Capital Management LLC (0.64%), Bank of New York Mellon Corp (0.27%) and Virtu Financial LLC (0.21%). View Institutional Ownership Trends for Akers Biosciences. Which major investors are selling Akers Biosciences stock? AKER stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Akers Biosciences. Which major investors are buying Akers Biosciences stock? AKER stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Virtu Financial LLC. View Insider Buying and Selling for Akers Biosciences. How do I buy shares of Akers Biosciences? Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Akers Biosciences' stock price today? One share of AKER stock can currently be purchased for approximately $1.06. How big of a company is Akers Biosciences? Akers Biosciences has a market capitalization of $13.23 million and generates $3.93 million in revenue each year. What is Akers Biosciences' official website? The official website for Akers Biosciences is http://www.akerslaboratories.com. How can I contact Akers Biosciences? Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected] MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 200 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 399MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What is a Stop Order?